In today's first round matchup of The Motley Fool Better-Buy Tournament, Netflix squares off against Gilead Sciences in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.
Motley Fool Consumer Goods Editor Mark Reeth thinks Netflix (NFLX 2.50%) is poised for greater growth than ever before. The past year was a good one for the video streamer and DVD deliverer, with total subscriber count increasing by 4 million and its contribution margin improving by about 400 basis points; all of this helped the company become the S&P 500 and Nasdaq 100 best performing stock of 2013. As if that wasn't enough, Netflix has a strong pipeline of original content that will draw additional viewers, which will in turn continue to improve the company's top line.
Motley Fool analyst Max Macaluso makes the case for Gilead Sciences (GILD 1.57%) to move on to the next round. Gilead is one of today's biggest biotech companies, with a number of blockbuster drugs already on the market. It also recently launched a potential blockbuster hepatitis C treatment, Sovaldi, and its impressive pipeline also bodes well for the company's future.
Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better-Buy Bracket.
This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Cast your vote in the poll below the video!